Advertisement

Tanshinone IIA

  • Yu-Cai Chen
  • Lian-Hua Fang
  • Guan-Hua DuEmail author
Chapter

Abstract

Tanshinone IIA is extracted from the roots of Salvia miltiorrhiza Bge., which exhibits a variety of pharmacological effects, such as promoting blood circulation and opening the energy channels. In the long history of morphine R&D, the efficacy of tanshinone IIA is mainly concentrated in interfering with the pathological process of cardiovascular diseases. It can reduce intracellular calcium concentration, attenuate the damages from the reactive oxygen species to vascular endothelial cells, and lower the risk of atherosclerosis. For better water solubility, the sodium sulfonate group is introduced for clinical application. The research on tanshinone IIA continues. Current researches show that tanshinone may play a positive role in the treatment of a variety of diseases and has good clinical application prospects.

Keywords

Tanshinone IIA Cardiovascular disease Salvia miltiorrhiza Bge. 

References

  1. 1.
    Chen WZ. Pharmacological action of Salvia miltiorrhiza. Acta Pharm Sin. 1984;19(11):876–80.Google Scholar
  2. 2.
    Du GH, Zhang JT. The general situation and progress of the modern research of red sage root. Her Med. 2004;23(6):355–60.Google Scholar
  3. 3.
    Chen WZ, Dong YL, Wang CG, Ding GS. Pharmacological study of tanshinone IIA sodium sulfonate. Acta Pharm Sin. 1979;05:277–83.Google Scholar
  4. 4.
    Gao YG, Song YM, Yang YY, Tang JX, Liu WF. Pharmacological study of tanshinone. Acta Pharm Sin. 1979;14(02):75–82.Google Scholar
  5. 5.
    Hu H, Zhai C, Qian G, Gu A, Liu J, Ying F, et al. Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction. Pharm Biol. 2015;53(12):1752–8.CrossRefGoogle Scholar
  6. 6.
    Wang J, Jiang Q, Wan L, Yang K, Zhang Y, Chen Y, et al. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol. 2013;48(1):125–34.CrossRefGoogle Scholar
  7. 7.
    Zhang MT, Qian YH, Tang AQ. Advances in pharmacological effects of tanshinone IIA. Med Recapitulate. 2010;16(17):2661–4.Google Scholar
  8. 8.
    Bai FM. Clinical application of tanshinone IIA sodium sulfonate. China Pharm. 2012;23(31):2971–3.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Centre for Pharmaceutical Screening, Institute of Materia MedicaChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations